In the Media

Led by Prof. Tim Lu, Senti Biosciences has received $53 million in venture capital funding to launch their startup that will focus on cancer therapies, writes Jonathan Shieber for TechCrunch. Ideally, these therapies “are able to be controlled (programmed) at the cellular level and respond to conditions in a variety of ways,” Shieber explains.